HURA Stock Forecast & Price Target

TuHURA Biosciences is expected to have a positive outlook for its personalized cancer vaccine, IFx-2.0, in the treatment of melanoma due to the recent Orphan Drug Designation granted by the FDA and prior data showing a 50% response rate in anti-PD1 refractory patients. This development could potentially drive future upside for the company, as it is not currently included in their valuation. With a Buy rating and a price target of $10, investors should consider the potential for increased royalty fees and other revenues for TuHURA Biosciences in the long term.

TuHURA Biosciences is facing significant challenges in the immuno-oncology sector as they operate in a single reportable segment with therapies yet to be approved. These challenges are reflected in the recent decline of ~62% in HURA shares, making it an attractive entry point. The upcoming value inflection points such as the preliminary results from the Phase 1b/2a trial and phase 2 trial could expand the company's potential market, but top-line results from the Phase 3 trial are not expected until 1Q27, raising concerns about the company's financial stability.